Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications.
暂无分享,去创建一个
[1] M. Kollef. An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] J. Karlowsky,et al. Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001 , 2003, Antimicrobial Agents and Chemotherapy.
[3] J. Turnidge,et al. Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration , 2003, Antimicrobial Agents and Chemotherapy.
[4] J. Garnacho-Montero,et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] J. Turnidge,et al. Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid Chromatography , 2003, Antimicrobial Agents and Chemotherapy.
[6] L. B. Hovde,et al. Synergistic Activity of Colistin and Ceftazidime against Multiantibiotic-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model , 2003, Antimicrobial Agents and Chemotherapy.
[7] T. Nakamura,et al. Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. , 2003, The Journal of hospital infection.
[8] E. Giamarellos‐Bourboulis,et al. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. , 2002, Diagnostic microbiology and infectious disease.
[9] D. Raoult,et al. Colistin: an antimicrobial for the 21st century? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] M. Hodson,et al. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis , 2002, European Respiratory Journal.
[11] C. Cabellos,et al. Efficacy of Colistin versus β-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii , 2002, Antimicrobial Agents and Chemotherapy.
[12] H. Elphick,et al. Colistin stimulates the activity of neutrophil elastase and Pseudomonas aeruginosa elastase , 2002, European Respiratory Journal.
[13] D. Livermore,et al. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] J. Pachón,et al. Cerebrospinal Fluid Penetration and Pharmacokinetic/Pharmacodynamic Parameters of Intravenously Administered Colistin in a Case of Multidrug-Resistant Acinetobacter baumannii Meningitis , 2002, European Journal of Clinical Microbiology and Infectious Diseases.
[15] E. Giamarellos‐Bourboulis,et al. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. , 2001, Diagnostic microbiology and infectious disease.
[16] R. Stern,et al. The Pharmacokinetics of Colistin in Patients with Cystic Fibrosis , 2001, Journal of clinical pharmacology.
[17] J. Turnidge,et al. In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis , 2001, Antimicrobial Agents and Chemotherapy.
[18] Ronald N. Jones,et al. Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines , 2001, Journal of Clinical Microbiology.
[19] A. Coates,et al. Nebulizer choice for inhaled colistin treatment in cystic fibrosis. , 2001, Chest.
[20] D. Feola,et al. Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria , 1999, The Annals of pharmacotherapy.
[21] S. Segal-Maurer,et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] A. Levin,et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] T. Tani,et al. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[24] R. Wise,et al. A reassessment of the in-vitro activity of colistin sulphomethate sodium. , 1997, The Journal of antimicrobial chemotherapy.
[25] G. Harrison,et al. Toxicity of Colistin in Cystic Fibrosis Patients , 1991, DICP : the annals of pharmacotherapy.
[26] Francis O'Grady,et al. ANTIBIOTIC AND CHEMOTHERAPY , 1974, The Ulster Medical Journal.